Sugi Predict

Sugi Predict / Compounds / SCHEMBL1630474

SCHEMBL1630474

SCHEMBL1630474

CC(C)(C)OC(=O)N1CCC1CN

nearest known ligand 0.46

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ PDE8B O95263 1/20 0.39
▸ ATM Q13315 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ CTSK P43235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630475 1.00 HTT (0.43) HTTHSD17B10CHRM2CHRM1CHRM3
SCHEMBL1398690 1.00 HTT (0.43) HTTHSD17B10CHRM2CHRM1CHRM3
SCHEMBL337037 0.90 HSD17B10 (0.48) HSD17B10PDE8BATMSMN1; SMN2
SCHEMBL337349 0.90 HSD17B10 (0.48) HSD17B10PDE8BATMSMN1; SMN2
SCHEMBL205359 0.90 HSD17B10 (0.48) HSD17B10PDE8BATMSMN1; SMN2
Hydrochloric Acid SCHEMBL1026857 0.89 HSD17B10 (0.47) HSD17B10PDE8BATMSMN1; SMN2
Hydrochloric Acid SCHEMBL1027414 0.89 HSD17B10 (0.47) HSD17B10PDE8BATMSMN1; SMN2
SCHEMBL80021 0.89 PDE8B (0.49) HSD17B10HPGDPDE8BATMSMN1; SMN2
SCHEMBL283705 0.89 PDE8B (0.49) HSD17B10HPGDPDE8BATMSMN1; SMN2
SCHEMBL344947 0.89 PDE8B (0.49) HSD17B10HPGDPDE8BATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
US-20250250230-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-08-07 — — US disclosed
US-20250197402-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-06-19 — — US disclosed
EP-4508027-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2025-02-19 — — EP disclosed
US-20240262806-A1 INHIBITORS OF NLRP3 PCT THERAPEUTICS, INC. (US) 2024-08-08 — — US disclosed
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 — — CN disclosed
EP-4392414-A1 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-07-03 — — EP disclosed
CN-113149983-B Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2024-03-29 — — CN disclosed
WO-2023199091-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-19 — — WO disclosed
EP-3389654-B1 DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS MERCK SHARP & DOHME LLC (US) 2023-08-16 — — EP disclosed
US-20140142099-A1 Purinone Derivatives as Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2014-05-22 — — US disclosed
US-20130196974-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE HOFFMANN-LA ROCHE INC. 2013-08-01 — — US disclosed
WO-2013020993-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-02-14 — — WO disclosed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 — — US disclosed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 — — US disclosed
US-20100331294-A1 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2010-12-30 — — US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US disclosed
US-20080188452-A1 Macrocyclic Benzofused Pyrimidine Derivatives ABBVIE INC. 2008-08-07 — — US disclosed
WO-2008016643-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250230-A1 HETEROCYCLIC COMPOUND HCRTR2, HCRTR1, NPY2R HTT 570/4885HSD17B10 1513/4885CHRM2 381/4885
US-20080188452-A1 Macrocyclic Benzofused Pyrimidine Derivatives DPYD, TYMS, UMPS HTT 1222/4885HSD17B10 1213/4885CHRM2 4850/4885
US-20240262806-A1 INHIBITORS OF NLRP3 NLRP3, NOD1, NLRP1 HTT 2835/4885HSD17B10 2933/4885CHRM2 3978/4885
US-20140142099-A1 Purinone Derivatives as Tyrosine Kinase Inhibitors BMX, BLK, ITK HTT 2657/4885HSD17B10 4554/4885CHRM2 3965/4885
US-20130196974-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE CFTR, H1-10, RECQL HTT 2336/4885HSD17B10 1803/4885CHRM2 667/4885
US-20090012126-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 HTT 1911/4885HSD17B10 2787/4885CHRM2 36/4885
US-20100331294-A1 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES HRH2, HRH4, HRH3 HTT 3249/4885HSD17B10 3863/4885CHRM2 70/4885
US-20250197402-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK HTT 2961/4885HSD17B10 4087/4885CHRM2 4799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.